A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00269958
Recruitment Status : Completed
First Posted : December 26, 2005
Last Update Posted : May 17, 2011
Information provided by:
Janssen-Ortho Inc., Canada

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of two different dosing schedules of epoetin alfa versus placebo for decreasing the need for blood transfusions and preventing the occurrence of severe anemia during the period of time around total hip replacement surgery. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

Condition or disease Intervention/treatment Phase
Anemia Drug: epoetin alfa Phase 2

Detailed Description:
Major surgical procedures may require blood transfusions both during and after the operation. Agents that can increase the rate of red blood cell production would reduce the need for blood transfusions and reduce the occurrence of anemia. Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production. This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study in patients scheduled for total hip replacement surgery. This study will assess the effectiveness of epoetin alfa (starting either 5 or 10 days before hip replacement surgery and continuing though 3 days after surgery) in reducing the need for blood transfusions and the occurrence of anemia during the time period surrounding surgery. Hip replacement can be either the initial implant surgery or a second surgery on the same hip. Eligible patients will be assigned to one of three treatment groups. Group 1 will receive daily placebo injections under the skin for 14 days; Group 2 will receive a longer (14-day) course of daily epoetin alfa injections under the skin; and Group 3 will receive a shorter (9-day) course of daily epoetin alfa injections under the skin. Patients in Groups 2 and 3 will receive 300 units of epoetin alfa per kilogram of body weight per day in each daily injection. All patients will receive oral iron supplementation beginning 3 weeks prior to surgery and continuing through 1 week after surgery. All patients will also receive low-dose coumadin (sodium warfarin) for 7 days after surgery to prevent clotting in the deep veins. Effectiveness will be determined by the number of patients requiring transfusions and the number of patients who develop anemia (as measured by a hemoglobin level < 80 grams per liter). Effectiveness will also be determined by the total number of transfusions required, changes in red blood cell variables (hemoglobin, hematocrit, the number of developing red blood cells (reticulocytes), changes in the iron stores in the patient's blood, intensity of nursing care required, well-being assessments (measures of pain, shortness of breath, and energy level), and the number of days in the hospital after surgery. Safety evaluations will include the incidence of blood clots in the deep veins of the lower limbs, the incidence and severity of other adverse events, and changes in clinical laboratory test results and vital signs. The study hypothesis is that patients treated with epoetin alfa before, during, and after hip replacement surgery will require fewer blood transfusions and have a reduced occurrence of anemia compared with patients treated with placebo, and that the shorter course of epoetin alfa dosing (9 days) is as effective as the longer epoetin alfa course (14 days). 300 units epoetin alfa per kilogram (U/kg) injected under the skin 5 or 10 days before surgery, the day of surgery, and 3 days after surgery; or placebo injection for 14 days. Subjects receiving epoetin alfa for 5 days also received placebo for 5 days before starting epoetin alfa.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 208 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery
Actual Study Completion Date : December 1991

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Proportion of patients needing blood transfusions; proportion of patients who develop anemia (defined as hemoglobin <80 grams per liter).

Secondary Outcome Measures :
  1. Number of blood units transfused; changes in red cell variables (hemoglobin, hematocrit, and reticulocyte counts); iron stores; nursing needs; scores on well-being tests; number days in hospital after surgery; deep vein clots and other adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients scheduled for elective, first-time hip-replacement surgery or a second hip-replacement surgery (with surgery taking place within 48 hours of the scheduled time)
  • having a baseline hemoglobin between 110 and 160 grams per liter
  • with no significantly abnormal values for laboratory tests that would indicate an impaired ability to respond to epoetin alfa.

Exclusion Criteria:

  • Patients with a primary hematologic disease
  • having any clinically significant disease/dysfunction of the neurologic, pulmonary, endocrine, cardiovascular, gastrointestinal, or genitourinary systems
  • who have had a seizure disorder in the past 5 years, or who are currently on anticonvulsant therapy
  • having uncontrolled high blood pressure
  • currently experiencing an ongoing blood loss

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00269958

Sponsors and Collaborators
Janssen-Ortho Inc., Canada
Study Director: Janssen-Ortho Inc. Clinical Trial Janssen-Ortho Inc., Canada

Additional Information: Identifier: NCT00269958     History of Changes
Other Study ID Numbers: CR005887
First Posted: December 26, 2005    Key Record Dates
Last Update Posted: May 17, 2011
Last Verified: April 2010

Keywords provided by Janssen-Ortho Inc., Canada:
hip replacement
hip replacement surgery
blood transfusions

Additional relevant MeSH terms:
Hematologic Diseases
Epoetin Alfa